Download MendeleyIdentification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Albrecht, B.K., Gehling, V.S., Hewitt, M.C., Vaswani, R.G., Cote, A., Leblanc, Y., Nasveschuk, C.G., Bellon, S., Bergeron, L., Campbell, R., Cantone, N., Cooper, M.R., Cummings, R.T., Jayaram, H., Joshi, S., Mertz, J.A., Neiss, A., Normant, E., O'Meara, M., Pardo, E., Poy, F., Sandy, P., Supko, J., Sims, R.J., Harmange, J.C., Taylor, A.M., Audia, J.E.(2016) J Med Chem 59: 1330-1339
- PubMed: 26815195
- DOI: https://doi.org/10.1021/acs.jmedchem.5b01882
- Primary Citation of Related Structures:
5HLS, 5HM0 - PubMed Abstract:
In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-κB. Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clinical trials for hematological malignancies (CPI-0610).
Organizational Affiliation:
Constellation Pharmaceuticals , 215 First Street, Suite 200, Cambridge, Massachusetts 02142, United States.
